FR2503145B1 - Peptides apparentes aux interferons humains, anticorps obtenus a partir de ces peptides et adsorbants obtenus a partir de ces anticorps - Google Patents

Peptides apparentes aux interferons humains, anticorps obtenus a partir de ces peptides et adsorbants obtenus a partir de ces anticorps

Info

Publication number
FR2503145B1
FR2503145B1 FR8205522A FR8205522A FR2503145B1 FR 2503145 B1 FR2503145 B1 FR 2503145B1 FR 8205522 A FR8205522 A FR 8205522A FR 8205522 A FR8205522 A FR 8205522A FR 2503145 B1 FR2503145 B1 FR 2503145B1
Authority
FR
France
Prior art keywords
antibodies
peptides
adsorbents
human interferons
interferons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8205522A
Other languages
English (en)
Other versions
FR2503145A1 (fr
Inventor
Fumio Shimizu
Yasukazu Ohmoto
Kenichi Imagawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP56047840A external-priority patent/JPS57163351A/ja
Priority claimed from JP56102731A external-priority patent/JPS582749A/ja
Priority claimed from JP13312781A external-priority patent/JPS5835158A/ja
Priority claimed from JP13312881A external-priority patent/JPS5835156A/ja
Priority claimed from JP56133124A external-priority patent/JPS5835157A/ja
Priority claimed from JP56133129A external-priority patent/JPS5835155A/ja
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of FR2503145A1 publication Critical patent/FR2503145A1/fr
Application granted granted Critical
Publication of FR2503145B1 publication Critical patent/FR2503145B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/28—Bound to a nonpeptide drug, nonpeptide label, nonpeptide carrier, or a nonpeptide resin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR8205522A 1981-03-31 1982-03-31 Peptides apparentes aux interferons humains, anticorps obtenus a partir de ces peptides et adsorbants obtenus a partir de ces anticorps Expired FR2503145B1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP56047840A JPS57163351A (en) 1981-03-31 1981-03-31 N-terminal peptide of beta-type interferon
JP56102731A JPS582749A (ja) 1981-06-30 1981-06-30 アフイニテイ−クロマトグラフイ−用吸着体
JP13312781A JPS5835158A (ja) 1981-08-24 1981-08-24 螢光標識ペプチド及びそれを利用するヒトα型インタ−フエロンの測定法
JP13312881A JPS5835156A (ja) 1981-08-24 1981-08-24 螢光標識ペプチド及びそれを利用するヒトβ型インタ−フエロンの測定法
JP56133124A JPS5835157A (ja) 1981-08-24 1981-08-24 ヒトリムホブラストイドインターフェロンのｎ末端ペプチド
JP56133129A JPS5835155A (ja) 1981-08-24 1981-08-24 ヒトリムホブラストイドインターフェロンのｃ末端ペプチド

Publications (2)

Publication Number Publication Date
FR2503145A1 FR2503145A1 (fr) 1982-10-08
FR2503145B1 true FR2503145B1 (fr) 1986-12-19

Family

ID=27550292

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8205522A Expired FR2503145B1 (fr) 1981-03-31 1982-03-31 Peptides apparentes aux interferons humains, anticorps obtenus a partir de ces peptides et adsorbants obtenus a partir de ces anticorps

Country Status (6)

Country Link
US (1) US4474754A (fr)
CH (1) CH652411A5 (fr)
DE (1) DE3211263A1 (fr)
FR (1) FR2503145B1 (fr)
GB (1) GB2102810B (fr)
SE (1) SE457352B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2557458B1 (fr) * 1983-12-30 1987-09-04 Centre Nat Rech Scient Nouveaux anticorps capables de reconnaitre specifiquement des groupements hapteniques, leur preparation et leur application, et nouveaux antigenes permettant de les preparer
US4959457A (en) * 1984-05-31 1990-09-25 Genentech, Inc. Anti-lymphotoxin
US5912136A (en) * 1985-11-19 1999-06-15 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
US5700915A (en) * 1985-11-19 1997-12-23 Schering Corporations Human interleukin immunopurification processes
IT8820888A0 (it) * 1988-06-08 1988-06-08 Eniricerche Spa Peptidi di sintesi immunologicamente attivi per lapreparazione di vaccini antimalarici.
DE3841767A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
US5391713A (en) * 1989-06-20 1995-02-21 Bionative Ab Interferon purification process
SE468251B (sv) 1989-06-20 1992-11-30 Bionative Ab Reningsprocess foer interferon
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
WO2000068251A1 (fr) 1999-05-07 2000-11-16 The University Of Virginia Patent Foundation Production biologique de derives stable de glutamine et de polyglutamine dans des organismes transgeniques et leur utilisation a des fins therapeutiques
JP2004529851A (ja) * 2000-09-12 2004-09-30 ジーントロール バイオセラピューティクス， インコーポレイテッド ヒトサイトカインの混合物を含む組成物およびその産生方法
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
DE60239522D1 (de) * 2001-01-09 2011-05-05 Baylor Res Inst Dallas Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FI20021761A0 (fi) * 2002-10-03 2002-10-03 Karyon Oy Ab Ltd Uusia lääkeaineita ja -valmisteita sekä niiden käyttö
AU2004289287A1 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
WO2005118884A1 (fr) * 2004-05-28 2005-12-15 The United States Of America As Represented By The Secretary Of The Navy Procede de diagnostic rapide de maladies infectieuses par detection et quantification de cytokines induites par des micro-organismes
JP2008515819A (ja) * 2004-10-07 2008-05-15 ウニベルジテート・チューリッヒ 乾癬の予防及び治療用ｉ型インターフェロンブロッキング剤
JP5837730B2 (ja) * 2005-02-10 2015-12-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗インターフェロンアルファモノクローナル抗体及び使用方法
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
RU2532832C2 (ru) 2008-05-07 2014-11-10 Аргос Терапьютикс, Инк. Гуманизированные антитела против альфа-интерферона человека
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
EP4335932A2 (fr) 2008-11-07 2024-03-13 Adaptive Biotechnologies Corporation Procédés de surveillance de conditions par analyse de séquence
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
EP2387627B1 (fr) 2009-01-15 2016-03-30 Adaptive Biotechnologies Corporation Profilage d'immunité adaptative et méthodes de génération d'anticorps monoclonaux
EP3409792B1 (fr) 2009-06-25 2023-09-20 Fred Hutchinson Cancer Center Procédé de mesure de l'immunité adaptative
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
AU2012316279A1 (en) * 2011-09-29 2014-04-17 Janssen Pharmaceutica Nv Process for the preparation of sulfamide derivatives
US9279159B2 (en) 2011-10-21 2016-03-08 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
CA2858070C (fr) 2011-12-09 2018-07-10 Adaptive Biotechnologies Corporation Diagnostic des malignites lymphoides et detection de maladie residuelle minimale
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
WO2013134162A2 (fr) 2012-03-05 2013-09-12 Sequenta, Inc. Détermination de chaînes appariées de récepteurs immuns à partir de sous-unités présentant une fréquence correspondante
CN104520440B (zh) 2012-05-08 2017-10-03 适应生物技术公司 用于测量和校准多重pcr反应中的扩增偏倚的组合物和方法
JP6449160B2 (ja) 2012-10-01 2019-01-09 アダプティブ バイオテクノロジーズ コーポレイション 適応免疫受容体多様性およびクローン性特性決定による免疫能力評価関連出願の相互参照
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
CA2941612A1 (fr) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Procedes dans lesquels on utilise des molecules synthetiques contenant des randomeres
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
EP3132059B1 (fr) 2014-04-17 2020-01-08 Adaptive Biotechnologies Corporation Quantification de génomes de cellules de l'immunité acquise dans un mélange complexe de cellules
AU2015339191A1 (en) 2014-10-29 2017-05-18 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341761A (en) * 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
DE3040824A1 (de) * 1980-10-30 1982-08-19 Dr. Karl Thomae Gmbh, 7950 Biberach Neues dekapeptid, verfahren zu seiner herstellung und verwendung
DE3040825A1 (de) * 1980-10-30 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach Neues tridekapeptid, verfahren zu seiner herstellung und verwendung

Also Published As

Publication number Publication date
DE3211263A1 (de) 1983-01-27
GB2102810A (en) 1983-02-09
DE3211263C2 (fr) 1987-09-24
GB2102810B (en) 1985-03-20
FR2503145A1 (fr) 1982-10-08
SE457352B (sv) 1988-12-19
US4474754A (en) 1984-10-02
CH652411A5 (de) 1985-11-15
SE8202012L (sv) 1982-10-01

Similar Documents

Publication Publication Date Title
FR2503145B1 (fr) Peptides apparentes aux interferons humains, anticorps obtenus a partir de ces peptides et adsorbants obtenus a partir de ces anticorps
IT1192709B (it) Meccanismo e metodo per istruire un paziente medante audioistruzioni
FR2510220B1 (fr) Joint d'etancheite
GB2196634B (en) Monoclonal antibodies to hiv and related peptides
ES272308Y (es) Banda de cierre de cremallera.
FR2517013B1 (fr) Joint d'etancheite
JPS54122539A (en) Reciprocating pedal type bicycle
BE891958A (fr) Joint d'etancheite
FR2631239B1 (fr) Anticorps monoclonal humain et hybridome le produisant
FR2522104B1 (fr) Joint d'etancheite ondule
ES275074Y (es) Conjunto de estanqueidad
ES270624Y (es) Banda de cierre de cremallera.
DK355483A (da) Monoklonale antistoffer til krydsafstemning af humant vaev
AU9132882A (en) Human immunoglobulin
NO161840C (no) Fremgangsmaate og anordning for frembringelse av en stroemning bestaaende av i det minste to faser.
FR2601963B1 (fr) Heterohybridomes produisant des anticorps monoclonaux anti-rhesus d humains.
FR2517786B1 (fr) Unite d'etancheite
GB2111527B (en) Monoclonal antibodies to human leucocyte interferon
ES511115A0 (es) "aparato de obturacion de una canalizacion".
DK49686D0 (da) Antigeniske peptider
NO173116C (no) Segment-deskriptorenhet
EP0205046A3 (en) Monoclonal antibody to human protein c
GB2125046B (en) Human leucocyte pepsin like enzyme
IT1233005B (it) Anticorpo umano monoclonale, composizione terapeutica che lo contiene linea cellulare capace di produrre l'anticorpo, procedimento per la sua produzione
BE887406A (fr) Hotte d'evacuation de vapeurs

Legal Events

Date Code Title Description
ST Notification of lapse